In clinical trials involving patients with rheumatoid arthritis, tocilizumab, the only anti-IL-6R mAb currently under investigation for BD (including a few cases of GIBD), appeared to pose a risk of serious and opportunistic infections, similar to anti-TNF-α agents in clinical use [52,73]. Here, TNF is linked to rheumatoid arthritis.